Neurocrine Biosciences | NBIX - 债务利息支出



金融业
股票价格
USD
资产
USD 4.91B
现金及等价物
USD 266.5M
销售成本
USD 13.8M
流动资产
USD 2.44B
流动负债
USD 831.7M
债务
USD 406.2M
EBIT
USD 214.6M
EBITDA
USD 193.3M
员工
1.8K
EPS每股收益
USD 1.94
股本和储备
USD 3.41B
销售毛利
USD 800.7M
债务利息支出
USD 1.1M
贷款资金
USD 169.5M
市值
USD 15.75B
净收入
USD 197.9M
营业费用
USD 599.9M
营业利润
USD 214.6M
普通股股本
USD 100.6M
PE价格收益
28.09
税前利润
USD 246.8M
销售收入
USD 811M
销售和管理费用
USD 318.5M
股票
USD 64.5M
贸易债权人
USD 691.3M
应收帐款人
USD 768.1M


债务利息支出 更改 日
AbbVie USD 645M 69M 2026-03
Acadia Pharmaceuticals USD 0 4.12M 2024-09
Agios Pharmaceuticals USD 1.18B 4.3B 2026-03
ALKERMES USD 20.89M 8.62M 2026-03
Alnylam Pharmaceuticals USD 69.29M 60.05M 2026-03
Amgen USD 657M 4M 2026-03
Biogen USD 72.6M 12.6M 2025-06
BioMarin Pharmaceutical USD 14.96M 12.18M 2026-03
Cytokinetics USD 33.34M 3M 2026-03
Enanta Pharmaceuticals USD 1.96M 620K 2024-12
Exelixis USD 23.4M 3.9M 2023-09
Gilead Sciences USD 240M 15M 2026-03
Halozyme Therapeutics USD 5.51M 597K 2026-03
Incyte USD 569K 13K 2026-03
Ionis Pharmaceuticals USD 17M 1000K 2026-03
Nektar Therapeutics USD 9.77M 3.75M 2025-12
Neurocrine Biosciences USD 1.1M 0 2024-03
Pfizer USD 671M 40M 2026-03
Prothena USD 349.89M 347.27M 2026-03
Regeneron Pharmaceuticals USD 12.9M 700K 2026-03
Repligen USD 5.58M 83K 2026-03
Rigel Pharmaceuticals USD 2.06M 31K 2024-09
Sarepta Therapeutics USD 20.84M 13.28M 2025-12
Teva Pharmaceutical Industries USD 216M 4M 2026-03
Ultragenyx Pharmaceutical USD 21M 2M 2026-03
Vertex Pharmaceuticals USD 3.3M 0 2025-12
Xoma USD 3.4M 150K 2024-06